|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Matt_Gline
|
|
gptkbp:country
|
gptkb:Switzerland
gptkb:United_States
|
|
gptkbp:focus
|
drug development
acquisition of underdeveloped drugs
|
|
gptkbp:foundedBy
|
gptkb:Vivek_Ramaswamy
|
|
gptkbp:foundedYear
|
2014
|
|
gptkbp:headquartersLocation
|
gptkb:New_York_City
Basel
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roivant Sciences
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:notableCollaboration
|
gptkb:Pfizer
gptkb:Sumitomo_Dainippon_Pharma
|
|
gptkbp:notableEvent
|
IPO in 2021 via SPAC merger
|
|
gptkbp:notableProduct
|
gptkb:batoclimab
gptkb:relugolix
Vtama (tapinarof)
|
|
gptkbp:numberOfEmployees
|
over 900 (as of 2023)
|
|
gptkbp:parentCompany
|
gptkb:Roivant_Sciences_Ltd.
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:ROIV
|
|
gptkbp:subsidiary
|
gptkb:Genevant_Sciences
gptkb:Datavant
gptkb:Dermavant_Sciences
gptkb:Enzyvant_Sciences
gptkb:Immunovant
gptkb:Myovant_Sciences
gptkb:Urovant_Sciences
|
|
gptkbp:website
|
https://www.roivant.com/
|
|
gptkbp:bfsParent
|
gptkb:麻省理工學院
|
|
gptkbp:bfsLayer
|
4
|